Jazz Pharmaceuticals
JAZZ
484 hedge funds and large institutions have $7.33B invested in Jazz Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 62 funds opening new positions, 161 increasing their positions, 179 reducing their positions, and 44 closing their positions.
166% more call options, than puts
Call options by funds: $38.8M | Put options by funds: $14.6M
41% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 44
3% more funds holding
Funds holding: 471 → 484 (+13)
4% more capital invested
Capital invested by funds: $7.05B → $7.33B (+$279M)
0.96% more ownership
Funds ownership: 88.55% → 89.51% (+0.96%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
10% less repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 179
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$41M |
| 2 |
Los Angeles Capital Management
Los Angeles,
California
|
+$36.5M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$31.9M |
| 4 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$25.5M |
| 5 |
Aristotle Capital Management
Los Angeles,
California
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$42.4M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$42.1M |
| 3 |
JP Morgan Chase
New York
|
-$36.1M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$26.5M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$24.8M |
JAZZ Hedge Fund Activity: Q3 2023 in Review
484 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q3 2023, worth a combined $7.33B — up 4% from $7.05B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new JAZZ positions and 44 closed out — a net gain of 18 holders — while 161 added to existing stakes and 179 trimmed.
The largest buyer was BlackRock, adding an estimated $41M. The largest seller was Redmile Group, exiting entirely with an estimated $42.4M sold.
- 484 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q3 2023, up from 471 in Q2 2023.
- Funds reported $7.33B of Jazz Pharmaceuticals stock for Q3 2023, up 4% quarter-over-quarter.
- 62 funds opened new Jazz Pharmaceuticals positions in Q3 2023 and 44 closed out, a net change of +18 holders.
- The largest Jazz Pharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $41M added.
- The largest Jazz Pharmaceuticals seller in Q3 2023 was Redmile Group, an estimated $42.4M sold.
Based on aggregated 13F filings for Q3 2023.